Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

J. Horti, E. Juhasz, Z. Monostori, K. Maeda, S. Eckhardt, I. Bodrogi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Methods: Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2; adequate organ function; and age ≥20 and 2. Pharmacokinetic samples were collected during each treatment course. Results: Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and Cmax) of TZT-1027 tended to increase linearly with dose. Conclusions: DLTs included neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The MTD was 4.8 mg/m 2. The recommended phase II study dose of TZT-1027 is 4.8 mg/m 2 administered every 3-4 weeks.

Original languageEnglish
Pages (from-to)173-180
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume62
Issue number1
DOIs
Publication statusPublished - Jun 2008

Fingerprint

dolastatin 10
Neutropenia
Non-Small Cell Lung Carcinoma
Pharmacokinetics
Cells
Derivatives
Maximum Tolerated Dose
Myalgia
Toxicity
Neuralgia
Fever
Oncology
Therapeutics
Refractory materials
Alopecia
Leukopenia
Anorexia
Constipation
Nausea
Area Under Curve

Keywords

  • Dolastatin
  • Non-small cell lung cancer
  • Phase I study
  • TZT-1027

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. / Horti, J.; Juhasz, E.; Monostori, Z.; Maeda, K.; Eckhardt, S.; Bodrogi, I.

In: Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1, 06.2008, p. 173-180.

Research output: Contribution to journalArticle

@article{3c014538c21a444fa119eb27c6ac9c8c,
title = "Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer",
abstract = "Purpose: The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Methods: Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2; adequate organ function; and age ≥20 and 2. Pharmacokinetic samples were collected during each treatment course. Results: Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and Cmax) of TZT-1027 tended to increase linearly with dose. Conclusions: DLTs included neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The MTD was 4.8 mg/m 2. The recommended phase II study dose of TZT-1027 is 4.8 mg/m 2 administered every 3-4 weeks.",
keywords = "Dolastatin, Non-small cell lung cancer, Phase I study, TZT-1027",
author = "J. Horti and E. Juhasz and Z. Monostori and K. Maeda and S. Eckhardt and I. Bodrogi",
year = "2008",
month = "6",
doi = "10.1007/s00280-007-0665-7",
language = "English",
volume = "62",
pages = "173--180",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

AU - Horti, J.

AU - Juhasz, E.

AU - Monostori, Z.

AU - Maeda, K.

AU - Eckhardt, S.

AU - Bodrogi, I.

PY - 2008/6

Y1 - 2008/6

N2 - Purpose: The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Methods: Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2; adequate organ function; and age ≥20 and 2. Pharmacokinetic samples were collected during each treatment course. Results: Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and Cmax) of TZT-1027 tended to increase linearly with dose. Conclusions: DLTs included neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The MTD was 4.8 mg/m 2. The recommended phase II study dose of TZT-1027 is 4.8 mg/m 2 administered every 3-4 weeks.

AB - Purpose: The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Methods: Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2; adequate organ function; and age ≥20 and 2. Pharmacokinetic samples were collected during each treatment course. Results: Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and Cmax) of TZT-1027 tended to increase linearly with dose. Conclusions: DLTs included neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The MTD was 4.8 mg/m 2. The recommended phase II study dose of TZT-1027 is 4.8 mg/m 2 administered every 3-4 weeks.

KW - Dolastatin

KW - Non-small cell lung cancer

KW - Phase I study

KW - TZT-1027

UR - http://www.scopus.com/inward/record.url?scp=42149130973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149130973&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0665-7

DO - 10.1007/s00280-007-0665-7

M3 - Article

C2 - 18214483

AN - SCOPUS:42149130973

VL - 62

SP - 173

EP - 180

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -